Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TransMedics (TMDX) EBT (2018 - 2026)

TransMedics has reported EBT over the past 8 years, most recently at -$84.7 million for Q4 2025.

  • For Q4 2025, EBT fell 199.05% year-over-year to -$84.7 million; the TTM value through Dec 2025 reached $1.2 million, up 153.25%, while the annual FY2025 figure was $1.2 million, 153.25% up from the prior year.
  • EBT for Q4 2025 was -$84.7 million at TransMedics, down from $23.0 million in the prior quarter.
  • Over five years, EBT peaked at $36.2 million in Q2 2025 and troughed at -$84.7 million in Q4 2025.
  • A 5-year average of -$1.7 million and a median of -$4.7 million in 2022 define the central range for EBT.
  • Biggest five-year swings in EBT: crashed 263.56% in 2023 and later skyrocketed 1340.1% in 2024.
  • Year by year, EBT stood at $31.7 million in 2021, then plummeted by 121.16% to -$6.7 million in 2022, then skyrocketed by 561.14% to $30.9 million in 2023, then plummeted by 191.68% to -$28.3 million in 2024, then crashed by 199.05% to -$84.7 million in 2025.
  • Business Quant data shows EBT for TMDX at -$84.7 million in Q4 2025, $23.0 million in Q3 2025, and $36.2 million in Q2 2025.